

Monoclonal Antibody to Human p21 ras (Multidrug Resistance)

Catalog No.:	DM081S
Quantity:	0.5 ml
Concentration:	0.15 - 0.16 mg/ml
Host / Isotype:	Mouse / IgG1
Clone:	NCC-RAS-001
Immunogen:	Recombinant C-H-ras p21(val-12)
Applications:	Western Blot. Immunohistochemistry on frozen and paraffin embedded sections. Recommended positive control: Subpopulation of Lymphocytes (2-3+), macrophages (1-2+) and fibroblasts (1-2+) as well as many normal Tissue elements (1-4+) can be used as internal positive specimen controls. For an expanded list of positive Tissues, see reference 5. The optimal dilution varies depending on antigen expression and density. Other applications not tested. Optimal dilutions of this antibody are dependent on conditions and should be determined by the user. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Specificity:	The human c(cellular)-ras genes are dormant protooncogenes that can be activated to participate in uncontrolled cell growth principally by somatic point mutation or by over expression. The majority of invasive cancers of breast showed amplified levels of p21H-ras expression, whereas in situ cancers had lower levels. The final staining intensity was found to vary as a function of cell differentiation. Cellular Localization: nuclear.
Storage:	Store the antibody at 4°C. Do not freeze! Shelf life: one year from despatch. Aliquoting Instructions: Do not dilute the entire reconstituted solution at once. Withdraw aliquots as needed with a micropipette and keep concentrated stock at 4C. Dilute according to the particular application being used. In general, the 0.05M Borate pH 8.0 containing 0.15M Sodium Chloride, 0.05% Sodium Azide, is a good diluent to use with most antibodies. Avoid diluting the entire contents of the vial at once since the diluted solution may have reduced stability.
General Readings:	<ol style="list-style-type: none">1. Hiwasa T, et al, Biomed Biochim Acta 50:579, 1991.2. Craig MA, et al, Intl J Canc 46: 133, 1990.3. Reynolds SH, et al, Proc Natl Acad Sci USA 88: 1085, 1991.4. Chin K-V, et al, Science 255: 459, 1992.5. Bos, JL, Mut Res, 195: 255, 1988.6. Bos, JL, Cancer Res, 49: 4682, 1989.7. Kanai, T, et al, Japan J Cancer Res, 78: 1314, 1987.

8. Simon, MI, et al, Science, 262: 802, 1991.
9. Hart, IR and Easty, D, Semin Cancer Biol, 2: 87, 1991.
10. Thor, A, et al, Lab Invest, 55: 603, 1986.
11. Furth, ME, et al, Oncogen